Global Syndromic Multiplex Diagnostic Market – Industry Trends and Forecast to 2029
The worldwide rise in infectious disease cases is a growing concern. These diseases can spread through various means, including indirect transmission, direct contact, and person-to-person transmission. In 2020, the United States recorded approximately 53,544 deaths from pneumonia and influenza, as reported by the Centers for Disease Control and Prevention (CDC). The surge in infectious diseases has a notable impact on the demand for syndromic multiplex diagnostics, which are used for molecular diagnostic purposes.
For access to the complete report, visit this link: https://www.databridgemarketresearch.com/reports/global-syndromic-multiplex-diagnostic-market
Data Bridge Market Research’s analysis reveals that the Syndromic Multiplex Diagnostic Market is growing at a CAGR of 8.70% from 2022 to 2029. It is projected to reach USD 5,765.24 million by 2029, a significant increase from USD 2,957.88 million in 2021. The growing prevalence of infectious diseases is a major driving force behind this growth. Syndromic multiplex diagnostics have the ability to swiftly pinpoint the cause of an infection, leading to early treatment and better patient outcomes. The increasing demand for precise and rapid diagnostic tests is another driving factor. Syndromic multiplex diagnostics offer both accuracy and speed, which are crucial in the early detection of diseases. Additionally, the development of new multiplexing technologies is contributing to market expansion. These technologies allow for the testing of multiple pathogens in a single sample, enhancing diagnostic accuracy and speed.
Key Market Drivers:
- Growing Prevalence of Diseases: The market is primarily driven by the increasing disease burden witnessed in recent years. This heightened need for reliable and timely test results is contributing to market growth over the forecast period. Notably, chronic respiratory disorders are impacting over one billion people globally, and there is a higher prevalence of severe asthma in emerging economies in the Middle East and Africa. Multiplex panels have been designed to detect such rare disorders.
The syndromic multiplex diagnostic market is segmented based on product and services, infection type, disease, panel type, and end-user.
- Products and Services: This segment is divided into reagents & consumables, instruments, software, accessories, and services. Reagents and consumables are expected to dominate the market, accounting for 69.95% of the share due to the increasing demand for these products in the diagnosis of various infectious diseases.
- Infection Type: Segmentation in this category includes viral, bacterial, parasites, and fungal. The viral segment is projected to be the leader with a 52.54% share, mainly driven by the rising number of diagnostic tests for viral diseases.
- Disease: The market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis, meningitis, and others. Respiratory infections are anticipated to dominate the market with a 47.23% share due to the growing adoption of syndromic multiplex diagnostic tests for respiratory infection diagnosis.
- Panel Type: Panels are categorized as respiratory panel, Gi-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel, and others. The respiratory panel segment is expected to dominate the market with a 47.27% share, as it is widely used for the diagnosis of respiratory infections.
- End User: The global syndromic multiplex diagnostic market serves clinical laboratories, hospitals, pharmaceutical and biotechnology companies, institutes, and others. Hospitals are expected to dominate the market with a 52.30% share, as they conduct numerous infectious disease diagnostic tests and are a trusted point of contact for patients.
Key market players include Seegene Inc., Luminex Corporation, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid, QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Akonni Biosystems, Inc., Biocartis, QuantuMDx Group Ltd., Robert Bosch GmbH, Applied BioCode, Inc., Prominex Inc., Nanomix, Inc., Curetis (a subsidiary of OpGen, Inc.), and MiRXES Pte Ltd.
The market has seen significant developments, including the commercial launch of the RT-Direct multiplex COVID-19 RT-PCR test kit by Cipla in 2022. This kit can detect multiple strains of COVID-19, including the Omicron variant, addressing the global shortage of syndromic multiplex diagnostic tests. Hologic also introduced the Novodiag System in Europe in 2021, offering an automated molecular diagnostic solution for infectious diseases and antimicrobial resistance. Eurofins launched a multiplex PCR Assay for rapid detection of the B.1.617 SARS-CoV-2 variant in the same year.
- North America: The dominant region for the syndromic multiplex diagnostic market during the forecast period, driven by the increasing prevalence of infectious diseases and the growing demand for accurate and rapid diagnostic tests.
- Asia-Pacific: Estimated to be the fastest-growing region due to a high level of awareness about the benefits of this technology and the increasing adoption of new healthcare technologies.